Malignant pleural effusions (MPE) are a common pathology, treated by respiratory
physicians and thoracic surgeons alike. In recent years, several well-designed randomized …

Background Malignant pleural effusions (MPE) are a frequent cause of dyspnea and
discomfort at the end of cancer patients' lives. The tunneled indwelling pleural catheter …

INTRODUCTION The discovery of malignant cells in pleural fluid and/or parietal pleura
signifies disseminated or advanced disease and a reduced life expectancy in patients with …

Introduction Malignant pleural effusions (MPEs) are a common cause of dyspnea in patients
with advanced cancer. Tunnelled pleural catheters (TPCs) can be used in patients with this …

A total of 21 659 pleural aspirations or drain insertions were conducted in England in
2019/2020 with a combined cost of£ 13.4 million. 1 There are now a variety of different …

Malignant pleural effusions (MPEs) are an important complication for patients with
intrathoracic and extrathoracic malignancies. Median survival after diagnosis of an MPE is 4 …

The aim of this study was to review systematically the available evidence on pleurodesis for
malignant effusion, focusing on the choice of the agents, route of delivery and other …

Goals/objectives To review the scientific evidence on symptoms and specific complications
that are associated with lung cancer, and the methods available to palliate those symptoms …

The majority of patients who acquire lung cancer will have troublesome symptoms at some
time during the course of their disease. Some of the symptoms are common to many types of …

Malignant pleural effusion (MPE) is a sign of advanced cancer and is associated with
significant symptom burden and mortality. To date, management has been palliative in …